RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST

Molecular Cancer Research

Volumn 11, Issue 6, 2013, Pages 616-627

  Sun, Daochun ^a   Haddad, Ramsi ^a,b,c   Kraniak, Janice M ^a   Horne, Steven D ^a   Tainsky, Michael A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WINDSOR   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NEUROFIBROMIN; RAS PROTEIN; SHORT HAIRPIN RNA;

ARTICLE; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; PHENOTYPE; PRIORITY JOURNAL;

BONE MORPHOGENETIC PROTEIN 2; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; NERVE SHEATH NEOPLASMS; NEUROFIBROMIN 1; PHENOTYPE; PHOSPHORYLATION; PYRAZOLES; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 84879300153     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0593     Document Type: Article

References (57)

1. Mattingly RR, Kraniak JM, Dilworth JT, Mathieu P, Bealmear B, Nowak JE, et al. The mitogen-activated protein kinase/extracellular signalregulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther 2006;316:456-65.
2. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990;63:843-9.
3. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311-4.
4. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 1986;314:1010-5.
5. Matsui I, Tanimura M, Kobayashi N, Sawada T, Nagahara N, Akatsuka J. Neurofibromatosis type 1 and childhood cancer. Cancer 1993;72: 2746-54.
6. Le LQ, Liu C, Shipman T, Chen Z, Suter U, Parada LF. Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. Cancer Res 2011;71:4686-95.
7. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-2.
8. Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Evans DG, et al. Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. Acta Neuropathol 2012;123:369-80.
9. Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ Jr, Mattingly RR, et al. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. Cancer Biol Ther 2008;7: 1938-46.
10. Lee PR, Cohen JE, Tendi EA, Farrer R, GH DEV, Becker KG, et al. Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells. Neuron Glia Biol 2004;1:135-47.
11. Watson MA, Perry A, Tihan T, Prayson RA, Guha A, Bridge J, et al. Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 2004;14: 297-303.
12. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006;66:2584-91.
13. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009;1: 236-48.
14. Reynolds JE, Fletcher JA, Lytle CH, Nie L, Morton CC, Diehl SR. Molecular characterization of a 17q11.2 translocation in a malignant schwannoma cell line. Hum Genet 1992;90:450-6.
15. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992;69:265-73.
16. Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res 2006;12:5533-42.
17. Dahlberg WK, Little JB, Fletcher JA, Suit HD, Okunieff P. Radiosensi-tivity in vitro of human soft tissue sarcoma cell lines and skin fibroblasts derived from the same patients. Int J Radiat Biol 1993;63:191-8.
18. Kraniak JM, Sun D, Mattingly RR, Reiners JJ Jr, Tainsky MA. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Mol Cell Biochem 2010;344:267-76.
19. Liu C, Tian G, Tu Y, Fu J, Lan C, Wu N. Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas. Jpn J Clin Oncol 2009;39:625-31.
20. Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005;65: 448-56.
21. Arnold SF, Tims E, McGrath BE. Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2. Cytokine 1999;11:1031-7.
22. Gordon KJ, Kirkbride KC, How T, Blobe GC. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis 2009;30:238-48.
23. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 2003;24:1445-54.
24. Werner T. Bioinformatics applications for pathway analysis of micro-array data. Curr Opin Biotechnol 2008;19:50-4.
25. Liang G, Bansal G, Xie Z, Druey KM. RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J Biol Chem 2009;284:21719-27.
26. 1- to S-phase transition. Oncogene 2007;26:3227-39.
27. Stow LR, Jacobs ME, Wingo CS, Cain BD. Endothelin-1 gene regulation. FASEB J 2011;25:16-28.
28. Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther 2011;10:336-46.
29. St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, et al. NT5E mutations and arterial calcifications. N Engl J Med 2011;364: 432-42.
30. Edwards NL, Magilavy DB, Cassidy JT, Fox IH. Lymphocyte ecto-5'-nucleotidase deficiency in agammaglobulinemia. Science 1978;201: 628-30.
31. Zhi X, Wang Y, Zhou X, Yu J, Jian R, Tang S, et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci 2010;101:2561-9.
32. Singh A, Morris RJ. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev 2010;21:299-313.
33. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005;19:2783-810.
34. Barkan B, Kloog Y, Ehrlich M. Phenotypic reversion of invasive neu-rofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling. Mol Cancer Ther 2011;10:1317-26.
35. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998;42:351-60.
36. Clement JH, Raida M, Sanger J, Bicknell R, Liu J, Naumann A, et al. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol 2005;27:401-7.
37. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFss and BMP pathways. Cell Signal 2011;23: 1831-42.
38. Ismat FA, Xu J, Lu MM, Epstein JA. The neurofibromin GAP-related domain rescues endothelial but not neural crest development in Nf1 mice. J Clin Invest 2006;116:2378-84.
39. Ho IS, Hannan F, Guo HF, Hakker I, Zhong Y. Distinct functional domains of neurofibromatosis type 1 regulate immediate versus long-term memory formation. J Neurosci 2007;27:6852-7.
40. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006;24:507-16.
41. Steib JP, Bouchaib J, Walter A, Schuller S, Charles YP. Could an osteoinductor result in degeneration of a neurofibroma in NF1? Eur Spine J 2010;19(Suppl 2):S220-5.
42. Fritz DT, Liu D, Xu J, Jiang S, Rogers MB. Conservation of Bmp2 post-transcriptional regulatory mechanisms. J Biol Chem 2004;279: 48950-8.
43. Williams LA, Bhargav D, Diwan AD. Unveiling the bmp13 enigma: redundant morphogen or crucial regulator? Int J Biol Sci 2008;4: 318-29.
44. Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol 2010;5: 245-53.
45. Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res 2010;316:24-37.
46. Peart TM, Correa RJ, Valdes YR, Dimattia GE, Shepherd TG. BMP signalling controls the malignant potential of ascites-derived human epithelial ovarian cancer spheroids via AKT kinase activation. Clin Exp Metastasis 2012;29:293-313.
47. +/- and c-kit-dependent bone marrow. Cell 2008;135:437-48.
48. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994;8:1019-29.
49. Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002;4:105-11.
50. Jiang W, Jiang HF, Pan CS, Cai DY, Qi YF, Pang YZ, et al. Relationship between the contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of spontaneously hypertensive rats. Hypertens Res 2004;27:109-17.
51. Tsuruda T, Jougasaki M, Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lee SC, et al. Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heart. Regul Pept 2003;112:161-6.
52. Romppanen H, Marttila M, Magga J, Vuolteenaho O, Kinnunen P, Szokodi I, et al. Adrenomedullin gene expression in the rat heart is stimulated by acute pressure overload: blunted effect in experimental hypertension. Endocrinology 1997;138:2636-9.
53. Montani D, Coulet F, Girerd B, Eyries M, Bergot E, Mal H, et al. Pulmonary hypertension in patients with neurofibromatosis type I. Medicine 2011;90:201-11.
54. Demarchi I, Genoni G, Prodam F, Petri A, Busti A, Cortese L, et al. [Neurofibromatosis type 1 and hypertension in pediatrics: case report]. Minerva Pediatr 2011;63:335-9.
55. Xu J, Ismat FA, Wang T, Lu MM, Antonucci N, Epstein JA. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 2009;105:304-11.
56. Chen M, Lin YQ, Xie SL, Wang JF. Mitogen-activated protein kinase in endothelin-1-induced cardiac differentiation of mouse embryonic stem cells. J Cell Biochem 2010;111:1619-28.
57. Castro MG, Rodriguez-Pascual F, Magan-Marchal N, Reguero JR, Alonso-Montes C, Moris C, et al. Screening of the endothelin1 gene (EDN1) in a cohort of patients with essential left ventricular hypertrophy. Ann Hum Genet 2007;71(Pt 5):601-10.